Author

J. Colinge

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Assay:bulk RNA-seq· 5 Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Maraver· 2 shared A. Turtoi· 2 shared B. Orsetti· 2 shared C. Theillet· 2 shared E. Cornillot· 2 shared M. Alame· 2 shared V. Cacheux· 2 shared A. Abi-Khalil· 1 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Maraver

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

The transcription factor RIP140 regulates interferon γ signaling in breast cancer

S. Jalaguier, A. Kuehn, C. Petitpas, A. Dulom, R. Jacquemont, C. Assi, S. Sixou, U. Jeschke, J. Colinge, V. Cavailles

This study identifies RIP140 as a regulator of IFNγ signaling in breast cancer, showing its repression of IFNγ-induced GBP1 expression and its role in enhancing IFNγ's anti-tumor effects.

bioRxiv · Feb 15, 2024Cancer Biology

Cancer-associated Fibroblast Spatial Heterogeneity and EMILIN1 Expression in Cancer Stroma Modulate TGF-beta Activity and CD8+ T-Cell Infiltration in Breast Cancer

C. Honda, S. Kurozumi, T. Fujii, D. Pourquier, L. Khellaf, F. Boissiere, J. Horiguchi, T. Oyama, K. Shirabe, J. Colinge, T. Yokobori, A. Turtoi

This study identifies EMILIN1 as a TGF-beta inhibitor expressed in IFN-gamma CAFs that modulates TGF-beta activity and CD8+ T-cell infiltration in breast cancer.

bioRxiv · Sep 12, 2023 · PreprintCancer Biology

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

S. Figarol, C. Delahaye, R. Gence, R. Asslan, S. Pagano, C. Tardy, J. Colinge, J.-P. Villemin, A. Maraver, I. Ferrer, L. Paz-Ares, I. Lajoie-Mazenc, E. Clermont, A. Casanova, A. Pradines, , G. Favre

This study identifies early escapers as a rare cell population resistant to EGFR-TKi and shows that tipifarnib overcomes this resistance by targeting Rho/ROCK pathway and preventing relapse.

bioRxiv · Apr 1, 2022 · PreprintCancer Biology

The immune landscape of primary central nervous system diffuse large B cell lymphoma

M. Alame, E. Cornillot, V. Cacheux, V. Rigau, V. Costes-Martineau, V. Lacheretz-Szablewski, J. Colinge

This study identifies three immune subtypes of PCNSL and their associations with survival and signaling pathways, suggesting immune stratification and TIM-3 as therapeutic targets.

bioRxiv · Aug 17, 2020Cancer Biology

MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis

D. Kantar, E. Bousquet Mur, M. Mancini, V. Slaninova, Y. Ben Salah, L. Costa, E. Forest, P. Lassus, C. Geminard, F. Boissiere-Michot, B. Orsetti, C. Theillet, J. Colinge, C. Benistant, A. Maraver, , A. Djiane

The paper shows that MAGI1 loss in luminal breast cancer promotes tumorigenesis by activating the AMOTL2/p38 stress pathway, which is inhibited by MAGI1.

bioRxiv · Jun 13, 2020Cancer Biology

The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities

M. Alame, E. Cornillot, V. Cacheux, G. Tosato, M. Four, L. De Oliveira, S. Gofflot, P. Delvenne, E. Turtoi, S. Cabello-Aguilar, M. Nishiyama, A. Turtoi, V. Costes Martineau, J. Colinge

This study characterizes the molecular landscape and microenvironment of salivary duct carcinoma, identifying immune checkpoints and stromal features that suggest new therapeutic strategies.

bioRxiv · Oct 21, 2019Cancer Biology

Distinct oncogenes drive distinct genome and epigenome alterations in human mammary epithelial cells

C. Fonti, A. Saumet, A. Abi-Khalil, B. Orsetti, W. Jacot, E. Cleroux, A. Bender, M. Dumas, E. Schmitt, J. Colinge, M. Weber, C. Sardet, S. du Manoir, C. Theillet

This study shows that activating different oncogenes in human mammary epithelial cells leads to distinct genetic and epigenetic changes, suggesting oncogene activation shapes breast cancer subtypes.

bioRxiv · Jun 11, 2018Cancer Biology